Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
ConditionGlaucoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Pennsylvania
About this trial
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial (DECLARE) is a multi-center, outcome-masked, randomized clinical trial. The purpose of this study is to compare glaucoma drainage device implantation in the anterior chamber (front part of the eye) and sulcus (small space between iris and front chamber of the eye) in efforts to minimize cell loss in the eye.
Eligibility criteria
Qualifiers
Medically uncontrolled glaucoma requiring GDD or GDD combined with phacoemulsification as the planned surgical procedure
Candidate for GDD implantation for ciliary sulcus and AC tube
Age greater than or equal to 18 years old
Disqualifiers
Preexisting corneal condition that would affect the corneal endothelium or previous corneal transplant
Presence or history of Cypass Micro-Stent
Previous GDD, Xen Gel Stent or Preserflo MicroShunt removed less than 6 months before surgery
Presence of GDD implantation, Xen Gel Stent, of Preserflo MicroShunt
Trial design
Treatments tested in this trial
- Sulcus tube placement
- Anterior chamber (AC) tube placement
Treatment groups
226 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Pennsylvania
Lead sponsor
National Eye Institute (NEI)
Collaborator
University of California, San Francisco
Collaborator
Stanford University
Collaborator
Source ClinicalTrials.gov